1. Marcellin P, Boyer N. Transition of care between paediatric and adult gastroenterology. Chronic viral hepatitis. Best Pract Res Clin Gastroenterol 2003;17:259-275. 12676118.
2. Bartenschlager R, Lohmann V. Replication of the hepatitis C virus. Baillieres Best Pract Res Clin Gastroenterol 2000;14:241-254. 10890319.
3. Appel N, Schaller T, Penin F, Bartenschlager R. From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem 2006;281:9833-9936. 16407182.
6. Zeuzem S, Sulkowski M, Lawitz E, Rustgi V, Lurie Y, Grigorescu M, et al. Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment-naive, chronic hepatitis C genotype 1 (CHCG1) patients [Abstract]. J Hepatol 2009;50S:S377.
7. Nelson D, Benhamou Y, Chuang WL, Lawitz E, Flisiak R, Rodriguez-Torres M, et al. Efficacy and safety results od albinterferon alfa-2b in combination with ribavirin in interferon alfa treatment naive patients with genotype 2 or 3 chronic hepatitis C [Abstract]. J Hepatol 2009;50S:S378.
8. Lawitz E, Younossi ZM, Shiffman M, Gordon S, Ghalib R, Long W, et al. Randomized trial comparing systemic and local reactions to controlled-release interferon alfa2b and pegylated - interferon alfa2b in hepatitis C patients who failed prior treatment [Abstract]. J Hepatol 2009;50S:S231.
9. Shiffman M, Lawitz E, Zaman A, Vierling J, Yoffe B, Freeman J, et al. Peg-IFN-l: Antiviral activity and safety profile in a 4-week phase 1b study in relapsed genotype 1 hepatitis C infection [Abstract]. J Hepatol 2009;50S:S237.
11. McHutchison JG, Patel K, Pockros P, Nyberg L, Pianko S, Yu RZ, et al. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hepatol 2006;44:88-96. 16274834.
12. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436:933-938. 16107832.
15. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003;300:1145-1148. 12702807.
17. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850. 19403903.
18. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838. 19403902.
19. Manns M, Muir A, Adda N, Jacobson I, Afdhal N, Heathcote J, et al. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy: SVR results of the PROVE3 study [Abstract]. J Hepatol 2009;50S:S379.
21. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-1278. 17408662.
22. Susser S, Welker MW, Zettler M, Wohnsland A, Hughes E, Ralston R, et al. Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders treated with boceprevir [Abstract]. J Hepatol 2008;48(S2):S29.
23. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D, et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus peginterferon TM (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C[Abstract]. J Hepatol 2009;50S:4.
24. Forestier N, Larrey D, Marcellin P, Benhamou Y, Guyader D, Bradford W, et al. Antiviral activity and safety of ITMN-191 in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus [Abstract]. J Hepatol 2009;50S:35.
25. Reesink H, Bergmann J, de Bruijne J, Weegink C, Van Lier J, Van Vliet A, et al. Safety and antiviral activity of SCH 900518 administered as monotherapy and in combination with peginterferon alfa-2b to naive and treatment-experienced HCV-1 infected patients [Abstract]. J Hepatol 2009;50S:S35-S36.
26. Manns M, Reesink H, Moreno C, Berg T, Benhamou Y, Horsmans Y, et al. OPERA-1 trial: Interim analysis of safety and antiviral activity of TMC435 in treatment-naive genotype 1 HCV patients [Abstract]. J Hepatol 2009;50S:S7.
27. Kukolj G BY, Manns MP, Bourliere M, Pol S, Schuchmann M, et al. BI 201335, a potent HCV NS3 protease inhibitor in treatment naive and -experienced chronic HCV genotype infection: Genotypic and phenotypic analysis of the NS3 protease domain. J Hepatol 2009;50S:347.
28. Manns Michael P., Bourliere Marc, Benhamou Yves, Pol Stanislas, Bonacini Maurizio, Berg Thomas, et al. Safety and antiviral activity of BI201335, a new HCV NS protease inhibitor, in treatment naive patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa 2a (P) and ribavirin(R) [Abstract]. Hepatology 2008;48:1133.
29. Manns Michael P., Bourliere Marc, Benhamou Yves, Schuchmann Marcus, Haussinger Dieter, Pol Stanislas, et al. Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa 2a (P) and ribavirin (R) for 28 days in P+R treatment experienced patients with chronic hepatitis C genotype 1 infection [Abstract]. Hepatology 2008;48:1151.
30. Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Wiedmann R, et al. MK-7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection [Abstract]. J Hepatol 2009;50S:S384.
31. Manns MP, Foster Gr, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 2007;6:991-1000. 18049473.
32. Afdhal N, O'Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, Lawitz E, et al. Valopicitabine (NM283), alone or with peg-interferon, compared to peg interferon/ribavirin (PEGIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to PEGIFN/RBV: one-year results [abstract]. J Hepatol 2007;46(S1):S5.
33. Valopicitabine development program placed on clinical hold in the United States [press release]. 2007. Cambridge (MA): Idenix Pharmaceuticals Inc.
34. Nelson D, Pockros PJ, Godofsky E, Rodriguez-Torres M, Everson G, Fried M, et al. High end-of-trearment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin [abstract]. J Hepatol 2008;48(S2):S371.
35. Pockros P, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW, et al. High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatology 2008;48:1349-1350. 18821613.
36. Reddy R, Rodriguez-Torres M, Gane E, Robson Richard, Lalezari Jacob, Everson Gregory T., et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy [abstract]. Hepatology 2007;46:862A.
37. Rodriguez-Torres Maribel, Lalezari Jay, Gane Edward J., DeJesus Edwin, Nelson David R., Everson Gregory T., et al. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with Peg-IFN and ribavirin: subanalysis by race/ethnicity, eight and HCV genotype [abstract]. Hepatology 2008;48:1160A.
38. Gane Edward J., Rodriguez-Torres Maribel, Nelson David R., Jacobson Ira M., McHutchison John G., Jeffers Lennox, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders; interim results of R7128 1500 mg BID with PEG-IFN and ribavirin for 28 days [abstract]. Hepatology 2008;48:1024A.
39. Pharmasset and Roche obtain FDA consent to start a phase 2b study with R7128 in treatment naive HCV patients [press release]. 2009. Princeton (NJ): Pharmasset Inc.
40. Cretton-Scott E, Perigaud C, Peyrottes S, Licklider L, Camire M, Larsson M, et al. In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication [abstract]. J Hepatol 2008;48(S2):S220.
41. Accessed February. 2009;14]. Accessed from Idenix website, Available at:
www.indenix.com.
43. Villano S RD, Harper D, Speth J, Chandra P, Shaw D, et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alfa-2b in treatment-naive patients with chronic HCV [abstract]. J Hepatol 2007;46(S1):S24.
44. Jacobson I, PP , Lalezari J, Lawitz E, Rodriguez-Torres M, DeJesus E, et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. J Hepatol 2009;50S:382.
45. Lawitz E, Cooper C, Rodriguez-Torres M, Ghalib R, Lalonde R, Sheikh A, et al. Safety, tolerability and antiviral activity of VCH-916, a novel non-nucleoside HCV polymerase inhibitor in patients with chronic HCV genotype 1 infection. J Hepatol 2009;50S:S37.
46. Nicolas O, Boivin I, Berneche-D'Amours A, Fex P, Denis F, Selliah S, et al. Genotypic and phenotypic analysis of HCV NS5B variants selected from patients treated with VCH-916 [Abstract]. J Hepatol 2009;50S:S349.
47. Lawitz E, Rodriguez-Torres M, DeMicco M, Nguyen T, Godofsky E, Appleman J, et al. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients [Abstract]. J Hepatol 2009;50S:S384.
48. Cooper C, Larouche R, Bourgault B, Chauret N, Proulx L. Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor VCH-222 following single dose administration in healthy volunteers and antiviral activity in HCV-infected individuals [Abstract]. J Hepatol 2009;50S:S342.
49. Brainard D, Wright DH, Sneddon K, Cummings C, Sun P, Valentine J, et al. Safety, tolerability, and pharmacokinetics after single and multiple doses of MK3281 in healthy subjects [Abstract]. J Hepatol 2009;50S:S341.
50. Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B, Elston R, et al. First in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: Safety, pharmacokinetics, and virologic results from INFORM-1 [Abstract]. J Hepatol 2009;50S:S380.
52. Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008;48:1761-1768. 19030166.
54. Codran A, Royer C, Jaeck D, Bastien-Valle M, Baumert TF, Kieny MP, et al. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol 2006;87:2583-2593. 16894197.
55. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-941. 9794763.
58. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801-805. 17325668.
60. Liu C, Coco D, Dong HJ, Eksioglu E, Zhu H, Ostrov D, et al. Novel antiviral small molecules that block hepatitis C virus cellular entry through the CD81 receptor. 2007;14th International Symposium on Hepatitis C and Related Viruses. september 9-13. Glasgow, UK.
63. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry
via activation of the scavenger receptor BI. J Biol Chem 2006;281:18285-18295. 16675450.
64. Koike K. Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH. Hepatol Res 2005;33:145-150. 16202646.
66. Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep 2004;4:194-198. 15132884.
68. Nanda KS, Ryan EJ, Murray BF, Brady JJ, McKenna MJ, Nolan N, et al. Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women. Clin Gastroenterol Hepatol 2009;7:894-899. 19558999.
69. Torres DM, Harrison SA. HCV replication and statin pleotropism: an adjuvant treatment panacea? Am J Gastroenterol 2008;103:1390-1392. 18479495.
71. Burnett JR. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia. Curr Opin Mol Ther 2006;8:461-467. 17078389.
72. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148-156. 17215532.
73. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003;44:1887-1901. 12837854.
75. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19:111-122. 15989969.
76. Flisiak R, Horban A, Gallay P, Bobardt M, Selvarajah S, Wiercinska-Drapalo A, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008;47:817-826. 18302285.
78. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003;39:1049-1055. 14642625.
79. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641. 15765399.
80. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004;39:880-890. 15057887.
81. Mbow ML, Sarisky RT. What is disrupting IFN-alpha's antiviral activity? Trends Biotechnol 2004;22:395-399. 15283983.
83. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007;45:1164-1171. 17465001.
85. Bernsmeier C, Duong FH, Christen V, Pugnale P, Negro F, Terracciano L, et al. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol 2008;49:429-440. 18486982.
86. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003;98:2751-2756. 14687828.
87. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-848. 14988838.
88. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366-1371. 16911678.
89. Romero-Gomez M, Diego M, Andrade RJ, Calleja JL, Salmeron J, Fernandez-Rodriguez CM, et al. Metformin with peginterferon alfa-2a and ribavirin in the treatment of naïve genotype 1 chronic hepatitis C patients with insulin resistance (TRIC-1): final results of a randomized and double blinded trial [abstract]. Hepatology 2008;48:380A.
92. Frederiksen KS, Wulf EM, Wassermann K, Sauerberg P, Fleckner J. Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. J Mol Endocrinol 2003;30:317-329. 12790802.
93. Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev 2007;3:33-39. 18220654.
94. Li X, Hansen PA, Xi L, Chandraratna RA, Burant CF. Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors. J Biol Chem 2005;280:38317-38327. 16179348.
97. de Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, et al. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 2006;23:107-114. 16393287.
99. Fujita N, Kaito M, Kai M, Sugimoto R, Tanaka H, Horiike S, et al. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. J Viral Hepat 2006;13:441-448. 16792537.
102. Watashi K, Inoue D, Hijikata M, Goto K, Aly HH, Shimotohno K. Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. J Biol Chem 2007;282:32765-32772. 17704057.
103. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007;67:1947-1967. 17722965.
104. Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008;77:56-63. 17888524.
105. Elazar M LM, McKenna S, Liu P, Gehrig EA, Elfert A, et al. Nitazoxanide (NTZ) is an inducer of eIF2a and PKR phosphorylation [abstract]. Hepatology 2008;48:1151A.
107. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009;136:856-862. 19135998.